AC
BSX icon

Ascend Capital’s Boston Scientific BSX Stock Holding History

Ascend Capital’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-197,187
Closed -$4.26M – 144
2016
Q4 		$4.26M Buy
+197,187
New +$4.3M 0.21% 106
2016
Q1 		– Sell
-548,705
Closed -$10.1M – 111
2015
Q4 		$10.1M Buy
+548,705
New +$9.83M 0.36% 79

Other funds holding BSX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Ascend Capital's BSX Position: Q1 2017 in Review

Ascend Capital sold out of Boston Scientific (BSX) in Q1 2017, closing a stake of 197,187 shares — an estimated $4.26M sold.

Ascend Capital first reported a position in BSX in Q4 2015 and held it in 2 quarters. The position peaked at $10.1M in Q4 2015. 552 funds tracked by Wall St. Rank hold BSX as of Q1 2017.

  • Ascend Capital reported no remaining Boston Scientific position as of Q1 2017 after selling out during the quarter.
  • Ascend Capital sold 197,187 Boston Scientific shares in Q1 2017, an estimated $4.26M.
  • Ascend Capital first reported a position in Boston Scientific in Q4 2015 and held it in 2 quarters.
  • Ascend Capital's Boston Scientific position peaked at $10.1M in Q4 2015.
  • 552 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.